introduction ms research day
TRANSCRIPT
“Our purpose is to translate cutting edge research andinnovation into measurable health gains for MSers inLondon, across the UK, and globally.”
Thank you
• Alison
• Jyoti
• David B / Gareth (MD1 & MD2)
• UCLP
• Barts-MS (QMUL, RLH, Basildon, Chelmsford, Southend)
• MS@UCL (UCL, UCLH)
• Royal Free (Watford, Chase Farm, L&D, Stevenage)
• Queens Romford
Trial activity targeting progressive pathology
MRI Events
1st clinicalattack
Time (Years)
Subclinical disease
Inflammation
Brain volume loss
Neuroaxonal loss
Dis
ease
Sev
erit
y
SPMSRRMS
1st MRI lesion
Relapses
CISRIS R-SPMS
RIS = radiologically isolated syndrome; CIS = clinically isolated syndrome, RRMS = relapsing-remitting MS; R-SPMS = relapsing secondary progressive MS; SPMS = secondary progressive MS; PPMS = primary progressive MS
SPMS: Natalizumab, Siponimod, DMF
Late SPMS: SMART STUDYfluoxetine, amiloride, riluzole
Early SPMS:oxcarbazepine
CIS: PHENYTOIN RRMS: ? DE-FLAMES STUDY
PPMS
PPMS: Fingolimod, Ocrelizumab, Laquinimod
SP&PPMS: Ibudilast
X
Treatment Update
DMT
1. Interferon-beta (Betaferon, Avonex, Rebif, Extavia)
2. Glatiramer Acetate (Copaxone)
3. Natalizumab (Tysabri)4. Fingolimod (Gilenya)
5. Teriflunomide (Aubagio)6. BG12 (Tecfidera)7. Alemtuzumab (Lemtrada)
8. Laquinimod9. Ocrelizumab10. Daclizumab11. Sopinimod
Symptomatic
1. THC/CBD (Sativex)
2. 4-aminopyridine (Fampridine)
3. VSN16 (Canbex)
• 10 minute talk• 10 Q&A• 10 minute table discussion
• 3 minute pitch from ‘MS Researcher’ at your table
• 7 minutes of Q’s• “MS Researcher” moves!
• 10 minute talk• 10 Q&A• 10 minute table discussion
• 3 minute pitch from ‘MS Researcher’ at your table
• 7 minutes of Q’s